Published in final edited form as:

Bioconjug Chem. 2007 ; 18(6): 1697–1700. doi:10.1021/bc700149u.

Use of a Genetically Engineered Protein for the Design of a Multivalent MRI Contrast Agent

Lindsay S. Karfeld^{§,~}, Steve R. Bull^{^,~}, Nicolynn E. Davis[§], Thomas J. Meade^{^,+,#}, and Annelise E. Barron^{§,^,*,⊥}

[§]Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL 60208

[^]Department of Chemistry, Northwestern University, Evanston, IL 60208

⁺Department of Biochemistry and Molecular and Cell Biology, Northwestern University, Evanston, IL 60208

[#]Feinberg School of Medicine, Northwestern University, Evanston, IL 60208

Abstract

The majority of clinically used contrast agents (CAs) for magnetic resonance imaging have low relaxivities and thus require high concentrations for signal enhancement. Research has turned to multivalent, macromolecular CAs to increase CA efficiency. However, previously developed macromolecular CAs do not provide high relaxivities, have limited biocompatibility, and/or do not have a structure that is readily modifiable to tailor to particular applications. We report a new family of multivalent, biomacromolecular, genetically engineered protein polymer-based CAs; the protein backbone contains evenly spaced lysines that are derivatized with gadolinium (Gd(III)) chelators. The protein's length and repeating amino acid sequence are genetically specified. We reproducibly obtained conjugates with an average of 8 – 9 Gd(III) chelators per protein. These multivalent CAs reproducibly provide a high relaxivity of 7.3 mM⁻¹s⁻¹ per Gd(III) and 62.6 mM⁻¹s⁻¹ per molecule. Furthermore, they can be incorporated into biomaterial hydrogels via chemical crosslinking of remaining free lysines, and provide a dramatic contrast enhancement. Thus, these protein polymer CAs could be a useful tool for following the evolution of tissue engineering scaffolds.

One significant barrier to the development of new generations of biocompatible materials, particularly tissue engineering hydrogels, is an inability to non-invasively evaluate the properties and performance of the biomaterial over time (1-6). Magnetic Resonance Imaging (MRI) is capable of whole animal or human imaging at high spatial and temporal resolution, and is an ideal modality for evaluating tissue engineering scaffolds *in vivo* (7-11). Exogenous contrast agents (CAs) increase the relaxation rate (1/T₁) of water protons and therefore improve image contrast. However, current clinically used CAs have low relaxivities (3-7 mM⁻¹s⁻¹) (12) and thus must be used at high concentrations for useful MRI signal enhancement (12).

T₁ CAs provide positive contrast by employing a paramagnetic ion (typically gadolinium, Gd (III)). The efficacy of a contrast agent is dominated by three parameters: *q*, the number of

Corresponding author. Annelise E. Barron, Department of Bioengineering, Stanford University, W300B James H. Clark Center, 318 Campus Drive, Stanford, CA 94305-5440; Phone: (650) 725-7665; Fax: (650) 723-8544; Email: annelise.barron@stanford.edu.

[~]Both authors contributed equally

[⊥]Present address: Department of Bioengineering, Stanford University, W300B James H. Clark Center, 318 Campus Drive, Stanford, CA 94305-5440; Phone: (650) 725-7665; Fax: (650) 723-8544; Email: annelise.barron@stanford.edu

We have designed, synthesized and characterized a macromolecular T₁ contrast agent based on artificial proteins. The backbone of these multivalent MRI contrast agents is derived from *E. coli* expression of monodisperse protein polymers. Gd(III) chelators were chemically conjugated to the backbone to create contrast agents that display high relaxivity in solution and when incorporated into a hydrogel. The covalent incorporation of these protein polymer contrast agents into a gel allows the potential for imaging tissue engineering scaffolds.

coordinated water molecules; τ_m , the residence lifetime; and τ_R , the rotational correlation time (13). Current clinically used small-molecule CAs are limited by their fast τ_R . More recently, these small-molecule CAs have been attached via covalent or non-covalent interactions to a number of macromolecules, including albumin (14), carbohydrates (15), linear polymers such as polylysine (16), dendrimers (17), viral capsids (18), and liposomes (19). These multivalent CA designs are advantageous because they increase τ_R , Gd(III) concentration, and CA retention *in vivo*. Previously, researchers have tracked tissue engineering scaffolds *in vivo* by MRI without using any exogenous CAs (20,21) or using soluble small-molecule CAs with a single Gd(III) chelator (22,23). Recently, Bull *et al.* synthesized a self-assembled peptide amphiphile (PA)-based biomaterial scaffold, in which an MRI CA was incorporated, creating the first biomaterial designed for subsequent MRI-based *in vivo* fate mapping (24).

Here, we report the design, synthesis, and characterization of a novel family of multivalent, macromolecular CAs based on genetically engineered proteins with repetitive sequences that form the backbone for subsequent chemical modification with Gd(III) chelators. These “protein polymer” CAs have high relaxivities in aqueous solution. Moreover, they provide a dramatic contrast enhancement when covalently crosslinked into protein-based hydrogels. The artificial protein polymers were generated by controlled cloning and recombinant protein expression in *E. coli*, and were designed to satisfy the specific criteria of water-solubility, controlled reactivity, and the ability to be crosslinked into hydrogels that could be useful for tissue engineering applications. In contrast to other biocompatible polymers such as dextran and other chemically synthesized and/or modified polymers, we can control the precise monomer composition, sequence, and chain length of these protein scaffolds. Affinity chromatography affords pure, monodisperse biopolymers with evenly spaced, primary amine reactive sites, which serve as an ideal scaffold for CA modification.

The protein polymer backbone we used comprises thirty repeats of the amino acid sequence GKAGTGSA, providing thirty reactive primary amines (ϵ -amino groups of lysines) that are available for derivatization (25). The 21,825 Da protein polymer (molar mass confirmed by MALDI; See Supporting Information (SI)) is water-soluble and can be produced in high yield. Circular dichroism spectroscopy shows that the protein adopts a random-coil (unfolded) configuration in aqueous solution (See SI) (26), thereby avoiding particular secondary structures that could potentially lead to decreased τ_R (such as a cylindrical α -helix). The macrocyclic chelate that coordinates the Gd(III) ion is a chemically synthesized derivative of 1,4,7,10-tetraaza cyclododecane-1,4,7,10-tetraacetic acid (DOTA) (27). The three acetate arms chelate the Gd(III) while the carboxylate group on the 5-carbon arm is used for covalent attachment to the primary amine of the lysine residues via amide bond formation.

A multi-step controlled cloning method was used to create the 720-base pair gene that encodes the protein polymer (26) and standard transformation and expression protocols were used to produce the 264-amino acid protein polymer, **1** (see SI) (28). The pET19b expression vector into which the gene was ligated contains an N-terminal histidine fusion tag, GH₁₀SSGHIDDDDKHM, enabling protein purification via Ni-NTA affinity chromatography under denaturing conditions (28). In a typical expression, up to ~ 60 mg/L culture medium are obtained after purification. Further details are given in SI.

The Gd(III) chelator was synthesized using a hydrogenation-labile protection scheme with benzyl 2-bromoacetate and benzyl 5-bromopentanoate as the chelating arms of the macrocycle (Scheme 1). The addition of three benzyl 2-bromoacetate arms to cyclen was followed by the addition of benzyl 5-bromopentanoate. Global deprotection by hydrogenation of the chelator and subsequent metallation with GdCl₃ afforded **6**, which subsequently was conjugated to the protein polymer. The synthesis and characterization of the chelator is described in the SI.

The coupling reaction between the lysine residues of **1** and **6** was carried out in aqueous 0.1 M 4-morpholineethanesulfonic acid (MES), 0.5 M NaCl buffer with 1-ethyl-3-carbodiimide hydrochloride (EDC) and *N*-hydroxysulfosuccinimide (Sulfo-NHS), which are water-soluble peptide bond-forming agents (Scheme 2) (29). We chose to conjugate premetallated chelators to the protein polymer in order to simplify the synthetic process, avoid solubility issues, and guarantee that each chelator contains a Gd(III) ion. MALDI-MS analysis of the conjugate confirmed an average of ~ 8 -9 out of a possible 31 lysines per molecule are typically derivatized using this procedure ($n=4$), but we have achieved up to 15 Gd(III)-conjugated sites per protein molecule in some cases. The conjugation efficiency of this reaction is limited by a competing hydrolysis reaction involving water molecules. The derivatization with Gd(III) chelators introduces a small degree of polydispersity, since the positions of the chelators along the backbone are different in each individual CA, but these CAs can still be well characterized by MALDI due to the monodispersity of the protein polymer backbone. As determined through relaxivity and Inductively Coupled Plasma (ICP)-MS measurements, the CAs display relaxivities of $7.3 \pm 0.4 \text{ mM}^{-1}\text{s}^{-1}$ per Gd(III) ion ($n=4$) and $62.6 \pm 3.5 \text{ mM}^{-1}\text{s}^{-1}$ per protein molecule complex, which is the product of the number of Gd(III) chelators per protein backbone times the relaxivity per Gd(III). Synthetic polymers such as dendrimers and metallofullerenes display molecular relaxivities of $\sim 35 \text{ mM}^{-1}\text{s}^{-1}$ (30) and $\sim 60 \text{ mM}^{-1}\text{s}^{-1}$ (31), respectively. There are a few examples of natural protein-based CAs that display greater molecular relaxivities (Cowpea chlorotic mottle virus, $\sim 200 - 400 \text{ mM}^{-1}\text{s}^{-1}$ per viral conjugate (32), apoferritin, $\sim 800 \text{ mM}^{-1}\text{s}^{-1}$ per protein complex (33), MS2 viral capsid, $\sim 7200 \text{ mM}^{-1}\text{s}^{-1}$ (18)). Even though some of these CAs have shown higher relaxivities per molecule, our new protein polymer CAs avoid some disadvantages associated with these other CAs. As compared with synthetic polymers, protein polymers consist of amino acids, so they are biodegradable and should not have any toxic byproducts (chelated Gd(III) is non-toxic). The above-mentioned natural protein CAs are less easily tunable and modifiable, so the relaxivity, size of the CAs, toxicity, *in vivo* circulation time, and mode of excretion cannot be as easily modulated. On the other hand, protein polymers can be precisely designed for the particular application and point of use; they can be customized to vary protein lengths and the spacing and number of lysines for conjugation to Gd(III) chelators. Additionally, these protein polymer CAs can be derivatized with other biological moieties for additional functionality, such as targeting and intracellular translocation.

To demonstrate one useful application of these new protein polymer-based CAs, tracking the evolution of tissue engineering hydrogels over time, we prepared 5.8% (w/v) protein-based hydrogels in aqueous solution in 5-mm NMR tubes for MR imaging experiments. The protein-CA conjugate, **7**, was doped into a solution of unconjugated protein polymer, **1**, and the free amines were crosslinked with 45 μL of 25% glutaraldehyde to form a gel (See SI). One advantage of these protein polymer-based CAs is that at least 50% of the primary amines on the backbone remain underivatized and are available for covalent crosslinking to form the hydrogel, as well as assisting in water-solubility. Thus, once crosslinked to other proteins within a hydrogel, the multivalent CAs can only be removed from the hydrogel as a result of hydrolysis of the scaffold and not as a result of diffusion. The MR images show that the hydrogel incorporating **7** is homogenous and exhibits dramatically higher MRI contrast than the hydrogel formed from a protein polymer control (Figure 1).

In conclusion, a combination of biosynthetic and chemical methods has been used to create high-contrast, multivalent, protein polymer-based MRI CAs. We have demonstrated a reliable synthetic protocol that allows conjugates to be characterized by MALDI and provides reproducible relaxivity results, both per molecule and per Gd(III). As shown in MR images, this protein polymer-based CA can be incorporated into a hydrogel and yields a dramatic contrast enhancement, which could be a useful tool for following the evolution of tissue engineering scaffolds *in vivo*. We plan to employ other crosslinking mechanisms and hydrogel

media to create a family of biocompatible tissue engineering scaffolds that can be fate-mapped *in vivo* by MRI, enabling tracking of both the cellular ingrowth and the scaffold degradation over time.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by NIH/NIBIB Grant Nos. 1-R01 EB003806 and 1-R01 EB005866, and the NIH/NRSA Biotechnology Training Grant (2-T32-GM008449). This work made use of the Analytical Services Laboratory of Northwestern University. We thank Keith Macrenaris for his assistance with ICP and MR image acquisition. We also thank Dr. Jong-In Won for his previous work that provide a basis for the concepts and designs in this paper.

References

1. Yang SF, Leong KF, Du ZH, Chua CK. The design of scaffolds for use in tissue engineering. Part 1. Traditional factors. *Tissue Engineering* 2001;7:679–689. [PubMed: 11749726]
2. Langer R, Tirrell DA. Designing materials for biology and medicine. *Nature* 2004;428:487–492. [PubMed: 15057821]
3. Liu W, Chen C. Engineering biomaterials to control cell function. *Materials Today* 2005;8:28–35.
4. Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. *Science* 2005;310:1139–1143. [PubMed: 16293750]
5. Pihlajamäki H, Kinnunen J, Bostman O. In vivo monitoring of the degradation process of bioresorbable polymeric implants using magnetic resonance imaging. *Biomaterials* 1997;18:1311–1315. [PubMed: 9307221]
6. Neves AA, Medcalf N, Smith M, Brindle KM. Evaluation of engineered meniscal cartilage constructs based on different scaffold geometries using magnetic resonance imaging and spectroscopy. *Tissue Engineering* 2006;12:53–62. [PubMed: 16499442]
7. Bull S, Guler M, Bras R, Venkatasubramanian P, Stupp S, Meade T. Magnetic resonance imaging of self-assembled biomaterial scaffolds. *Bioconjugate Chemistry* 2005;16:1343–1348. [PubMed: 16287227]
8. Cheery S. In vivo molecular and genomic imaging: new challenges for imaging physics. *Physics in Medicine and Biology* 2004;49:R13–R48. [PubMed: 15012005]
9. Huber M, Staubli A, Kustedjo K, Gray M, Shih J, Fraser S, Jacobs R, Meade T. Fluorescently detectable magnetic resonance imaging agents. *Bioconjugate Chemistry* 1998;9:242–249. [PubMed: 9548540]
10. Watanabe T. Recent topics in NMR imaging and MRI. *Magnetic Resonance in Medical Sciences* 2002;1:38–49. [PubMed: 16037667]
11. Bull S, Guler M, Bras R, Meade T, Stupp S. Self-assembled peptide amphiphile nanofibers conjugated to MRI contrast agents. *Nano Letters* 2005;5:1–4. [PubMed: 15792402]
12. Artemov D, Bhujwalla Z, Bulte J. Magnetic resonance imaging of cell surface receptors using targeted contrast agents. *Current Pharmaceutical Biotechnology* 2004;5:485–494. [PubMed: 15579038]
13. Merbach, AE.; Toth, E. *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*. John Wiley & Sons, Inc.; West Sussex, England: 2001.
14. Caravan P, Ellison J, McMurry T, Lauffer R. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. *Chemical Reviews* 1999;99:2293–2352. [PubMed: 11749483]
15. Sirlin C, Vera D, Corbell J, Caballero M, Buxton R, Mattrey R. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent. *Academic Radiology* 2004;11:1361–1369. [PubMed: 15596374]
16. Opsahl L, Uzgiris E, Vera D. Tumor imaging with a macromolecular paramagnetic contrast agent: gadopentetate dimeglumine-polylysine. *Academic Radiology* 1995;2:762–767. [PubMed: 9419637]

17. Langereis S, de Lussanet Q, van Genderen M, Meijer E, Beets-Tan R, Griffioen A, van Engelshoven J, Backes W. Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. *NMR in Biomedicine* 2006;19:133–141. [PubMed: 16450331]
18. Anderson EA, Isaacman S, Peabody DS, Wang EY, Canary JW, Kirshenbaum K. Viral nanoparticles donning a paramagnetic coat: Conjugation of MRI contrast agents to the MS2 capsid. *Nano Letters* 2006;6:1160–1164. [PubMed: 16771573]
19. Strijkers G, Mulder W, van Heeswijk R, Frederik P, Bomans P, Magusin P, Nicolay K. Relaxivity of liposomal paramagnetic MRI contrast agents. *Magma* 2005;18:186–192. [PubMed: 16155762]
20. Stroman PW, Dorvil JC, Marois Y, Poddevin N, Guidoin R. In vivo time course studies of the tissue responses to resorbable polylactic acid implants by means of MRI. *Magnetic Resonance in Medicine* 1999;42:210–214. [PubMed: 10398970]
21. Traore AS, Woerly S, Doan VD, Marois Y, Guidoin R. In vivo magnetic resonance imaging and relaxometry study of a porous hydrogel implanted in the trapezius muscle of rabbits. *Tissue Engineering* 2000;6:265–278. [PubMed: 10941221]
22. Barbash IM, Leor J, Feinberg MS, Tessone A, Aboulafia-Etzion S, Orenstein A, Ruiz-Cabello J, Cohen JS, Mardor Y. Interventional magnetic resonance imaging for guiding gene and cell transfer in the heart. *Heart* 2004;90:87–91. [PubMed: 14676253]
23. Cheng HLM, Chen J, Babyn PS, Farhat WA. Dynamic Gd-DTPA enhanced MRI as a surrogate marker of angiogenesis in tissue-engineered bladder constructs: A feasibility study in rabbits. *Journal of Magnetic Resonance Imaging* 2005;21:415–423. [PubMed: 15778952]
24. Bull SR, Guler MO, Bras RE, Meade TJ, Stupp SI. Self-assembled peptide amphiphile nanofibers conjugated to MRI contrast agents. *Nano Letters* 2005;5:1–4. [PubMed: 15792402]
25. Davis N, Ding S, Karfeld L, Barron A. Synthesis and characterization of a new class of cationic protein polymers for multivalent display and biomaterial applications. 2007unpublished results
26. Won J, Barron A. A new cloning method for the preparation of long repetitive polypeptides without a sequence requirement. *Macromolecules* 2002;35:8281–8287.
27. Artemov D, Mori N, Okollie B, Bhujwala Z. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. *Magnetic Resonance in Medicine* 2003;49:403–408. [PubMed: 12594741]
28. Ausbel, F. *Current Protocols in Molecular Biology*. J. Wiley & Sons Inc.; New York: 2001.
29. Hermanson, G. *Bioconjugate Chemistry*. Academic Press; San Diego: 1996.
30. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized MRI contrast agents. *Current Pharmaceutical Biotechnology* 2004;5:539–549. [PubMed: 15579043]
31. Mikawa M, Kato H, Okumura M, Narazaki M, Kanazawa Y, Miwa N, Shinohara H. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. *Bioconjugate Chemistry* 2001;12:510–514. [PubMed: 11459454]
32. Allen M, Bulte J, Liepold L, Basu G, Zywicke H, Frank J, Young M, Douglas T. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. *Magnetic Resonance in Medicine* 2005;54:807–812. [PubMed: 16155869]
33. Aime S, Frullano L, Crich SG. Compartmentalization of a gadolinium complex in the apoferritin cavity: A route to obtain high relaxivity contrast agents for magnetic resonance imaging. *Angewandte Chemie-International Edition* 2002;41:1017–1019.

Figure 1. MR images acquired at 14.1 Tesla with TR 250.0 ms, TE 10.2 ms: **a.** Glutaraldehyde-crosslinked hydrogel doped with **7** with an added Gd(III) concentration of 0.8 mmol **b.** the control hydrogel without contrast agent.

Scheme 1.

Synthesis of the Gd(III) chelator using a hydrogenation-labile global deprotection scheme. Gd (III) was chelated before conjugation to the protein to ensure all chelators contained Gd(III).

Scheme 2.

Conjugation of the Gd(III) chelator to the protein polymer backbone through amide bond formation using EDC and Sulfo-NHS, where ~ 8-9 chelators per protein molecule are available for conjugation.